Antibody-Based Strategies to Prevent and Treat Influenza
Passive immunization using antibodies is a promising alternative to other antiviral treatment options. The potential for seasonal protection arising from a single injection of antibodies is appealing and has been pursued for a number of infectious agents. However, until recently, antibody-based stra...
| Main Authors: | , , |
|---|---|
| Other Authors: | |
| Format: | Article |
| Language: | en_US |
| Published: |
Frontiers Research Foundation
2015
|
| Online Access: | http://hdl.handle.net/1721.1/98116 https://orcid.org/0000-0002-2085-7840 |
| _version_ | 1826196864680067072 |
|---|---|
| author | Shriver, Zachary Trevejo, Jose M. Sasisekharan, Ram |
| author2 | Massachusetts Institute of Technology. Department of Biological Engineering |
| author_facet | Massachusetts Institute of Technology. Department of Biological Engineering Shriver, Zachary Trevejo, Jose M. Sasisekharan, Ram |
| author_sort | Shriver, Zachary |
| collection | MIT |
| description | Passive immunization using antibodies is a promising alternative to other antiviral treatment options. The potential for seasonal protection arising from a single injection of antibodies is appealing and has been pursued for a number of infectious agents. However, until recently, antibody-based strategies to combat infectious agents have been hampered due to the fact that most antibodies have been found to be strain specific, with the virus evolving resistance in many cases. The discovery of broadly neutralizing antibodies (bNAbs) in influenza, dengue virus, and HIV, which bind to multiple, structurally diverse strains, has provided renewed interest in this area. This review will focus on new technologies that enable the discovery of bNAbs, the challenges and opportunities of immunotherapies as an important addition to existing antiviral therapy, and the role of antibody discovery in informing rational vaccine discovery – with agents targeting influenza specifically addressed. Multiple candidates have entered the clinic and raise the possibility that a single antibody or small combination of antibodies can effectively neutralize a wide variety of strains. However, challenges remain – including combating escape variants, pharmacodynamics of antibody distribution, and development of efficacy biomarkers beyond virologic endpoints. |
| first_indexed | 2024-09-23T10:38:52Z |
| format | Article |
| id | mit-1721.1/98116 |
| institution | Massachusetts Institute of Technology |
| language | en_US |
| last_indexed | 2024-09-23T10:38:52Z |
| publishDate | 2015 |
| publisher | Frontiers Research Foundation |
| record_format | dspace |
| spelling | mit-1721.1/981162022-09-30T22:00:09Z Antibody-Based Strategies to Prevent and Treat Influenza Shriver, Zachary Trevejo, Jose M. Sasisekharan, Ram Massachusetts Institute of Technology. Department of Biological Engineering Massachusetts Institute of Technology. School of Engineering Koch Institute for Integrative Cancer Research at MIT Sasisekharan, Ram Passive immunization using antibodies is a promising alternative to other antiviral treatment options. The potential for seasonal protection arising from a single injection of antibodies is appealing and has been pursued for a number of infectious agents. However, until recently, antibody-based strategies to combat infectious agents have been hampered due to the fact that most antibodies have been found to be strain specific, with the virus evolving resistance in many cases. The discovery of broadly neutralizing antibodies (bNAbs) in influenza, dengue virus, and HIV, which bind to multiple, structurally diverse strains, has provided renewed interest in this area. This review will focus on new technologies that enable the discovery of bNAbs, the challenges and opportunities of immunotherapies as an important addition to existing antiviral therapy, and the role of antibody discovery in informing rational vaccine discovery – with agents targeting influenza specifically addressed. Multiple candidates have entered the clinic and raise the possibility that a single antibody or small combination of antibodies can effectively neutralize a wide variety of strains. However, challenges remain – including combating escape variants, pharmacodynamics of antibody distribution, and development of efficacy biomarkers beyond virologic endpoints. National Institutes of Health (U.S.) (Award 1R01AI111395) National Institutes of Health (U.S.) (Merit Award R37 GM057073-13) Singapore. National Research Foundation (Singapore-MIT Alliance for Research and Technology) 2015-08-20T15:34:06Z 2015-08-20T15:34:06Z 2015-07 2015-04 Article http://purl.org/eprint/type/JournalArticle 1664-3224 http://hdl.handle.net/1721.1/98116 Shriver, Zachary, Jose M. Trevejo, and Ram Sasisekharan. “Antibody-Based Strategies to Prevent and Treat Influenza.” Frontiers in Immunology 6 (July 13, 2015). https://orcid.org/0000-0002-2085-7840 en_US http://dx.doi.org/10.3389/fimmu.2015.00315 Frontiers in Immunology Creative Commons Attribution http://creativecommons.org/licenses/by/4.0/ application/pdf Frontiers Research Foundation Frontiers Research Foundation |
| spellingShingle | Shriver, Zachary Trevejo, Jose M. Sasisekharan, Ram Antibody-Based Strategies to Prevent and Treat Influenza |
| title | Antibody-Based Strategies to Prevent and Treat Influenza |
| title_full | Antibody-Based Strategies to Prevent and Treat Influenza |
| title_fullStr | Antibody-Based Strategies to Prevent and Treat Influenza |
| title_full_unstemmed | Antibody-Based Strategies to Prevent and Treat Influenza |
| title_short | Antibody-Based Strategies to Prevent and Treat Influenza |
| title_sort | antibody based strategies to prevent and treat influenza |
| url | http://hdl.handle.net/1721.1/98116 https://orcid.org/0000-0002-2085-7840 |
| work_keys_str_mv | AT shriverzachary antibodybasedstrategiestopreventandtreatinfluenza AT trevejojosem antibodybasedstrategiestopreventandtreatinfluenza AT sasisekharanram antibodybasedstrategiestopreventandtreatinfluenza |